FDA regulations

Lars began by emphasizing the urgency of advancing biotechnology safely. I reassured him that this is possible, highlighting two key factors: aggressive private sector investment, federally funded basic research, and science-based regulation.

The Trump Administration issued two executive orders relating to biomedical science in recent days. The first involved the regulation of biotechnology products, and the second involved transparency in healthcare costs.

The value of computer-driven medical devices in capturing data is ubiquitous, but the real power of these systems will and do come from how recommendations that support the decision making of physicians and patients.

Yesterday, ACSH s Ariel Savransky attended the 2nd Annual E-cig conference in New York City.

Dr. Gilbert Ross in The American, May 14, 2014.